5.83

0.52% +0.03

Foghorn Therapeutics Inc (FHTX)

Overview News Price History Option Chain Financials Why FHTX Down? Discussions Forecast

Foghorn Therapeutics Inc stock is currently priced at $5.83, with a 24-hour trading volume of 215.68K. It has seen a +0.52% increased in the last 24 hours and a +6.78% rose in the past month. The chart indicates a potential bullish trend, as the stock is above the $5.82 pivot point. If it approaches the $5.99 resistance level, significant changes may occur.

Previous Close:

$5.80

Open:

$5.84

24h Volume:

215.68K

Market Cap:

$322.57M

Revenue:

$34.16M

Net Income/Loss:

$-98.43M

P/E Ratio:

-2.1277

EPS:

-2.74

Net Cash Flow:

$-119.33M

1W Performance:

+3.37%

1M Performance:

+6.78%

6M Performance:

+37.18%

1Y Performance:

-7.31%

1D Range:

$5.74

$6.129

52W Range:

$2.70

$9.97

Foghorn Therapeutics Inc Stock (FHTX) Company Profile

Name

Foghorn Therapeutics Inc

Sector

Healthcare (1198)

Industry

Biotechnology (691)

Phone

617-586-3100

Address

100 Binney Street, Suite 610, Cambridge

Employee

Twitter

Next Earnings Date

2024-06-26

Latest SEC Filings

FHTX's Discussions on Twitter

Foghorn Therapeutics Inc Stock (FHTX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Mar-28-23	Initiated	BofA Securities	Buy
Jan-05-23	Initiated	BMO Capital Markets	Outperform
Nov-22-21	Initiated	H.C. Wainwright	Buy
Nov-17-20	Initiated	Cowen	Outperform
Nov-17-20	Initiated	Goldman	Buy
Nov-17-20	Initiated	Morgan Stanley	Overweight
Nov-17-20	Initiated	Wedbush	Outperform

View All

Foghorn Therapeutics Inc Stock (FHTX) Latest News

Quarterly Metrics: Quick and Current Ratios for Foghorn Therapeutics Inc (FHTX) – DWinneX - The Dwinnex

The Dwinnex

Foghorn Therapeutics to Participate in Upcoming Investor Conferences in June - GlobeNewswire

GlobeNewswire

Foghorn Therapeutics to Participate in Upcoming Investor Conferences in June - Yahoo Finance

Yahoo Finance

Foghorn Therapeutics' $110 Million Common Stock Offering – Global Legal Chronicle - Global Legal Chronicle

Global Legal Chronicle

Take off with Foghorn Therapeutics Inc (FHTX): Get ready for trading – Sete News - SETE News

SETE News

Objective long/short (FHTX) Report - Stock Traders Daily

Stock Traders Daily

Foghorn Therapeutics Inc Stock (FHTX) Financials Data

Foghorn Therapeutics Inc (FHTX) Revenue 2024

FHTX reported a revenue (TTM) of $34.16 million for the quarter ending December 31, 2023, a +77.63% rise year-over-year.

Foghorn Therapeutics Inc (FHTX) Net Income 2024

FHTX net income (TTM) was -$98.43 million for the quarter ending December 31, 2023, a +9.60% increase year-over-year.

Foghorn Therapeutics Inc (FHTX) Cash Flow 2024

FHTX recorded a free cash flow (TTM) of -$119.33 million for the quarter ending December 31, 2023, a -162.02% decrease year-over-year.

Foghorn Therapeutics Inc (FHTX) Earnings per Share 2024

FHTX earnings per share (TTM) was -$2.34 for the quarter ending December 31, 2023, a +10.69% growth year-over-year.

Foghorn Therapeutics Inc., a biopharmaceutical company, discovers and develops medicines targeting genetically determined dependencies within the chromatin regulatory system. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. It is developing FHD-286, a small-molecule enzymatic inhibitor of BRG1 and BRM for the treatment of acute myeloid leukemia and uveal melanoma; and FHD-609, a small molecule protein degrader of BRD9 to treat patients with synovial sarcoma. The company is also developing preclinical and discovery programs, including selective BRM targeting non-small-cell lung cancer; and selective ARID1B modulators for bladder, ovarian, and endometrial cancer. It has a collaboration with Merck Sharp & Dohme Corp. to discover and develop novel oncology therapeutics against a transcription factor target. The company was founded in 2015 and is headquartered in Cambridge, Massachusetts.